The schedule advances two primary legal concepts: a technical place-based definition and a tiered application taxonomy.

1. Technical place-based definition , dispensary. The schedule provides a single-sentence definition: "dispensary means an area dedicated to storing and dispensing medicines" (sch.1-sec.1). That definition fixes the meaning of "dispensary" for the scope of the schedule. It is a functional definition tied to use ("dedicated to storing and dispensing medicines"), not to physical attributes, licensing status, or ownership. The scope is therefore behaviourally defined: a space becomes a dispensary by being dedicated to certain functions.

2. Tiered application taxonomy. The bulk of the schedule sets out three mutually exclusive categories of "application": tier 1, tier 2 and tier 3 (sch.2-sec.1). Each tier is defined by a combination of these variables:

   • number of applicants (1, 2, 3-5);
   • whether applicants are corporations (explicit caps on how many may be corporations); and
   • whether ownership involves ownership "as trustee" of one or more trusts (explicit limits on the number of trusts involved).

Tier 1 is framed narrowly. It includes:

• an application by one person whose ownership does not involve ownership as trustee of a trust, or involves ownership as trustee of only one trust; or
• an application by two persons provided at most one is a corporation and their joint ownership does not involve trusteeship other than ownership as trustee of at most one trust (sch.2-sec.1).

Tier 2 expands the permissible number of trusts and applicants:

• an application by one person where ownership as trustee involves only two trusts; or
• an application by two persons that is not tier 1 and involves at most one or two trusts as trustees; or
• an application by three, four or five persons provided not more than two are corporations and joint ownership involves at most one or two trusts (sch.2-sec.1).

Tier 3 is residual: any application that is not a tier 1 or tier 2 application falls into tier 3 (sch.2-sec.1).

The schedule repeats these definitions in multiple clauses and repeated bullet-like lines, which creates a dense textual field that attempts to capture edge cases by restating the same thresholds. The definitions are deterministic: if the enumerated factual conditions are met, the application is classified in that tier. The schedule does not provide examples, definitions of "application" or "pharmacy business", nor does it supply evidentiary standards to establish whether ownership is "as trustee" and how trusts are counted. It also does not provide the substantive consequences attached to each tier within this schedule.

The schedule directly affects persons who make "applications" that "relate to the ownership of the pharmacy business to which the application relates" (sch.2-sec.1). In practical terms, the participants affected are:

• Individual applicants who seek to acquire, register, or otherwise apply in respect of a pharmacy business. Such single-person applicants are placed into tier 1 if they do not own as trustee of more than one trust, into tier 2 if they own as trustee of exactly two trusts, and into tier 3 if neither of those descriptions fits (sch.2-sec.1).

• Joint applicants. The schedule explicitly contemplates joint applications made by two persons and by three, four or five persons (sch.2-sec.1). For two-person joint applications, tier qualification depends on whether not more than one applicant is a corporation and how many trusts are involved. For three to five person joint applications, tier 2 applies only where not more than two of the persons are corporations and the trust count is no more than two. Absent those conditions, the application falls into tier 3.

• Corporations as applicants. The schedule treats corporate applicants differently by placing caps on how many applicants within a joint application may be corporations: tier 1 allows no more than one corporate applicant in a two-person joint application; tier 2 allows not more than two corporate applicants in a three-five person application (sch.2-sec.1). Where the caps are exceeded, the application cannot qualify as tier 1 or tier 2 and will be tier 3.

• Trustees and trusts. The schedule directly implicates trusteeship. Ownership "as trustee of a trust" is the counting unit that changes tier categorisation (sch.2-sec.1). The schedule references ownership as trustee of "only 1 trust", "only 2 trusts", or no trusteeship. Thus, where an applicant holds ownership in trusteeship capacities, the number of distinct trusts for which the applicant is trustee determines tier placement.

• Administrators, decision-makers and record-holders. Although the schedule does not name the decision-maker who will classify applications or the process for submission, any administrative body that receives such applications will be affected because it must apply the tiering rules to incoming applications. That body will need to verify corporate status and trusteeship counts, and therefore will be involved indirectly.

The schedule is silent on broader stakeholders such as patients, suppliers, or professional registrants; it neither references professional registration nor sets operational obligations for the pharmacy business itself (apart from defining "dispensary" in sch.1-sec.1). In sum, the immediate burden and decision-making requirement fall on applicants and on the unspecified authority that processes their applications to determine which tier applies based on the enumerated factual criteria.

The schedule primarily imposes categorisation duties rather than operational duties. It creates duties of factual classification and rights that are implicit in a tiered regime.

Duties:

• Duty to establish factual status relevant to tiering. An applicant must ensure that the facts necessary to classify the application are ascertainable: number of applicants; whether each applicant is a corporation; and whether ownership involves ownership as trustee of one or more trusts (sch.2-sec.1). The schedule does not state how those facts are proven or what documents are required, but the act of classification is made conditional on those facts. Practically, therefore, applicants will need to compile evidence of corporate status and trust arrangements if the administering authority requires verification.

• Duty to specify the pharmacy business to which the application relates. Each tier definition is framed in relation to "the pharmacy business to which the application relates" (sch.2-sec.1). Applicants must therefore identify the specific pharmacy business in respect of which the ownership-related application is made. The schedule does not define "pharmacy business" beyond that phrase.

• Duty to account for trusteeship multiplicity. The schedule conditions tier assignment on whether ownership is as trustee of only one trust, only two trusts, or no trust (sch.2-sec.1). This imposes a duty on applicants to identify and count trusts where ownership is held in a trustee capacity.

Rights:

• Right to predictable classification based on enumerated criteria. Because the schedule sets out deterministic criteria for tiering, applicants have the right to be classified by reference to those criteria. That is, if an applicant satisfies the conditions for tier 1 as written (for example, single person owner with no trusteeship or only one trusteeship), then under the schedule the application is a tier 1 application (sch.2-sec.1).

• Residual right arising from tier 3 definition. The schedule clarifies that any application not captured by the tier 1 or tier 2 descriptions is a tier 3 application (sch.2-sec.1). This creates a right of residual categorisation: applicants who do not fit tier 1 or tier 2 are not unclassified; they are tier 3.

Not included in the schedule:

• There are no explicit procedural duties, timeframes, review rights, appeal rights, or disclosure obligations contained in this schedule. The schedule does not state who decides, how long decision-makers have, whether decisions are reviewable, or what sanctions apply for misstatements. Those duties and rights must therefore be found elsewhere or inferred by administrators but are not created by the schedule itself.

• The schedule contains no substantive operational duties tied to the "dispensary" definition; it merely defines the term (sch.1-sec.1). Any duties that depend on what constitutes a dispensary will arise from other provisions that reference this definition.

In short, the schedule creates a factual classification architecture, imposing duties on applicants to present the facts necessary for classification and granting, by definition, the right to a classification under the stated criteria. Procedural and enforcement rights and duties are absent from the text provided.

The schedule contains no penalty, sanction, or enforcement provisions. The supplied text is limited to definitions and tier rules; it does not include any clauses imposing fines, criminal liability, civil consequences or administrative sanctions for non-compliance with the definitions or for misstatement in application material. Specifically:

• There is no provision in sch.1 or sch.2 that prescribes penalties for incorrect classification, false statements about trusteeship, corporate status, or the number of applicants, or for misrepresenting whether a space is "dedicated to storing and dispensing medicines" (sch.1-sec.1; sch.2-sec.1).

• There is no mechanism in the schedule for auditing or verifying applicants beyond the criteria themselves. The text does not set out the powers of any decision-maker to request documents, to require declarations, or to impose sanctions if an applicant fails to prove a claimed status.

• The schedule includes a Fees heading (sch.2-pt.2) but provides no text under it in the supplied instrument. Therefore there are no fee amounts, fee-setting powers, waivers, or refund mechanisms expressed in the schedule as supplied.

Implications of silence:

• Because the schedule is silent about enforcement, any penalties, administrative processes, or compliance regimes that attach to the tiers must be provided by other provisions or instruments external to this schedule. The schedule therefore functions as a definitional foundation upon which enforcement rules may operate elsewhere, but it does not itself create enforcement tools.

• The absence of internal enforcement clauses creates an implementation risk: unless the administering authority or an accompanying statute supplies clear verification and sanctioning mechanisms, disputes about tier classification (for example, the correct count of trusts or corporate applicants) will lack an express statutory enforcement pathway within this schedule and will require reliance on external processes.

• For practitioners, the schedule therefore places emphasis on evidentiary preparation and cautious disclosure; the potential consequences of misclassification will depend entirely on external rules and are not specified here.

In short, the schedule defines and categorises but does not prescribe enforcement or penalties; any enforcement consequences must be traced to other statutory or regulatory instruments not included in the supplied text.

The schedule itself is narrow and does not reference other statutes, regulations, licencing regimes, or professional standards. It supplies definitional and classificatory content that is likely intended to operate within a larger regulatory framework, but those interactions are not explicit in the text provided. From the schedule alone, the following interaction points are observable or logically implied:

• Definitions as building blocks. The definition of "dispensary" (sch.1-sec.1) will interact with any other provision in the broader Act or subordinate instruments that references "dispensary". Where other provisions impose obligations, standards, or licencing conditions that hinge on the term "dispensary", they will inherit the schedule's functional definition: space dedicated to storing and dispensing medicines.

• Tiered procedures. The tier classifications (sch.2-sec.1) are designed to be used as input variables for other provisions. For example, tier status might determine filing fees, documentary requirements, timeframes, levels of scrutiny, or approval pathways. The schedule does not itself provide these linkages, so any interaction with fee regimes, exemptions or priority processing must be set out in other parts of the parent Act or in subsidiary instruments.

• Evidentiary interaction. The schedule introduces trustee-counting and corporate-counting rules. These factual categories will interact with laws governing trusts and corporate status insofar as those laws determine who counts as a trustee, how many trusts an entity may be trustee of, or how corporate identity is established. The schedule does not define "trust" or "trustee", so the normal legal definitions from the broader legal system will determine how trusts are counted when applying sch.2-sec.1.

• Procedural and remedial interaction. Because the schedule does not establish appeals, enforcement, or verification mechanisms, those functions must be supplied by other laws or rules. The effect of a misstatement or dispute about classification will therefore depend on external remedial regimes (not present in this schedule). The schedule’s silence means it defers to the broader legal architecture for remedies and enforcement.

• Administrative resource interaction. The need to verify corporate status and trusteeship means that administrative agencies applying this schedule will need to draw on corporate registers, trust documentation, or sworn declarations , again, the schedule does not prescribe which sources or standards of proof are authoritative.

Given the schedule’s laconic style, its interaction with other laws is primarily one of provision of building blocks: it supplies a definition and a taxonomy that other provisions should reference. The exact nature of those interactions , fees, procedural steps, enforcement, evidentiary burden , is absent and must be located in the larger statutory or regulatory framework that uses this schedule.

The supplied text contains no amendment history, commencement dates, or marginal notes indicating prior or subsequent changes to the schedule. The document as supplied comprises two parts: sch.1-pt.1 (Preliminary) with a single definition of "dispensary" (sch.1-sec.1), and sch.2-pt.1 (Preliminary) with an extended tiering definition (sch.2-sec.1), followed by a heading for sch.2-pt.2 Fees but no substantive fee provisions. There is no textual material indicating earlier versions, edits, insertions, or repeal annotations.

Operational consequences of that silence:

• The absence of amendment notes means practitioners cannot rely on the supplied schedule to trace its drafting history, policy changes, or the evolution of key terms. Any analysis of how the tiering regime originated, or whether the definition of "dispensary" has been altered, is not possible from this text alone.

• The repeated and duplicative clauses in sch.2-sec.1 suggest that the schedule may be a draft or an excerpt containing editorial duplication. However, the schedule does not contain explicit amendment markers or explanatory notes that would confirm this. Where repeated clauses exist verbatim or in variant formulation, it is not possible from the schedule alone to tell whether the repetitions reflect deliberate redundancy for emphasis or a drafting anomaly.

• Because there is a Fees part heading with no content, the schedule as supplied may be incomplete or may be intended to be read alongside other schedule parts or statutory sections that fill in the fee details. There is no notation in the text about deferral of fee amounts or relegation to regulations.

Practitioners needing a reliable legislative history, record of amendments, or the chronology of changes must therefore consult the authoritative parliamentary or legislative instruments that compile amendment histories and version changes; that material is not contained in the excerpt provided.

The schedule contains no references to cases, judicial interpretations, administrative determinations, or legal challenges. There are no named decisions, citations, or footnotes pointing to litigation that has construed the definitions or the tiering rules. Accordingly:

• There is no litigation history recorded in the supplied text that interprets "dispensary", counts trusts for tiering purposes, or construes the corporate caps in joint applications.

• Because the schedule introduces terms that are likely to be fact-sensitive and potentially contestable (for example, how to count trusts, whether a person "is a corporation" for the caps, or whether a physical area is "dedicated" to dispensing medicines), the absence of judicial guidance in the schedule means that early cases could shape interpretation, but none are recorded here.

• The repetition and multiple restatements of the tier definitions in sch.2-sec.1 may create fertile ground for litigation about textual ambiguity or legislative intent. The supplied instrument does not, however, report any such cases.

For any party or practitioner seeking precedential or interpretative guidance on the application of these provisions, the supplied schedule does not provide it. One must therefore consult external case law repositories, tribunal decisions or administrative determinations to identify any litigation that later interprets these provisions , none of which appear in the text at hand.

The text contains several features likely to cause practical problems or contested interpretations. These are not normative judgments; they are concrete risks arising from the schedule’s drafting and content.

1. Functional definition of "dispensary" lacks qualifiers. The definition is purely functional: "an area dedicated to storing and dispensing medicines" (sch.1-sec.1). There is no metric for what "dedicated" means, no threshold for the proportion of use that must be for storing or dispensing, and no exclusion for multi-use spaces. Organisations and regulators will therefore face immediate questions about whether shared spaces, overflow areas, or temporary storage areas qualify as dispensaries.

2. Counting trusts for trusteeship is potentially difficult. The tiering rules hinge on whether ownership "involves ownership as trustee of only 1 trust" or "only 2 trusts" (sch.2-sec.1). The schedule does not define "trust", "trustee", or how separate trusts are to be counted where trust families, sub-trusts, corporate trustees, or unit trusts are involved. This invites disputes about whether a suite of related trusts constitutes one trust for the purposes of the schedule or multiple trusts.

3. Corporate caps create structuring incentives. Because the number of corporate applicants permitted without elevating tier status is strictly limited (at most one corporate applicant in a two-person joint application for tier 1; not more than two corporate applicants in a three-five person joint application for tier 2) (sch.2-sec.1), parties may restructure ownership to avoid being classified into a higher tier. That incentive exists because the schedule ties tier status to the number of corporate applicants without explaining why corporate participation should change the regulatory treatment.

4. Repetition and duplicative clauses increase interpretive risk. sch.2-sec.1 contains numerous restatements of the same thresholds in slightly different clause fragments. Such repetition can produce uncertainty about whether variants alter meaning or are drafting artifacts. Parties may litigate which formulation controls if they are inconsistent or if one appears broader than another.

5. Silence on evidentiary standard and document types. The schedule requires counting and classification but is silent on how those factual claims are to be evidenced, who bears the burden of proof, and what penalties may apply for false statements (sch.2-sec.1). This gap means applicants face uncertainty about what documents will be accepted and whether disclosure of trust instruments, corporate registers or declarations will be required.

6. Fees heading without content. sch.2-pt.2 is titled Fees yet contains no fee-related clauses in the supplied text. This may indicate an omission in the excerpt or reliance on an external fee schedule. Practitioners should not assume fee levels or exemptions from the supplied schedule.

7. Residual tier 3 is a broad bucket. The definition of tier 3 as "an application other than a tier 1 application or tier 2 application" means a potentially large variety of factual scenarios are lumped together with no internal gradation (sch.2-sec.1). This can produce uneven regulatory treatment if rules elsewhere attach materially different consequences to tiers.

These "gotchas" show where the schedule requires amplification by administrative practice, subsidiary rules, or external statutory provisions in order to operate smoothly. Parties preparing or reviewing applications should be aware that the schedule sets thresholds but leaves many operational details unspecified.

The schedule imposes a narrow set of compliance primitives: ensure correct factual classification and be able to demonstrate the facts that determine tier status; and, where relevant, ensure that a space that is claimed as a dispensary plainly meets the functional definition. Practical compliance steps, tightly grounded on the schedule language, are as follows.

1. Determine the relevant application and the pharmacy business. Begin by identifying whether the instrument you are filing is an "application" that "relates to the pharmacy business" in question (sch.2-sec.1). The tiering rules are keyed to the ownership of a specified pharmacy business; ensure the application explicitly identifies the business to which it relates.

2. Count applicants and classify corporate status.

   • Record the exact number of applicants on the application form. If one applicant, evaluate the single-person criteria; if two, check the corporate cap; if three to five, check the corporate cap applicable to those tiers (sch.2-sec.1).
   • For joint applications, count how many applicants are corporations. For two-person joint applications, confirm that not more than one is a corporation to qualify for tier 1; for three-five person joint applications, confirm that not more than two are corporations to be eligible for tier 2 (sch.2-sec.1).

3. Audit trusteeship and count trusts.

   • For each applicant, determine whether any ownership is "as trustee of a trust". Where an applicant is a trustee, compile the trust documents and identify the number of distinct trusts for which the applicant holds ownership as trustee.
   • For single applicants: confirm whether trusteeship involves only one trust (tier 1), only two trusts (tier 2), or more/other arrangements (tier 3) (sch.2-sec.1).
   • For joint applicants: aggregate trusteeship counts across applicants as required by the tier definitions. The schedule does not specify aggregation rules explicitly, so record trust instruments carefully and be prepared to explain aggregation logic.

4. Document corporate and trust evidence. Although the schedule does not mandate documentary proof, administering authorities will likely require evidence. Collect:

   • corporate certificates of registration or equivalent proof of corporate status for corporate applicants;
   • trust deeds, trustee appointment records, and any variation documents to demonstrate the identity and number of trusts for trusteeship counting purposes.

5. Prepare a declaration of facts for tier classification. Given the absence of evidentiary rules in the schedule, submit a concise declaration that sets out:

   • the number of applicants;
   • which applicants are corporations;
   • whether each applicant holds ownership as trustee and, if so, for how many trusts;
   • the identity of the pharmacy business to which the application relates. This will materially reduce the risk of misclassification and provide a contemporaneous record if disputes arise.

6. Assess whether operational spaces meet the dispensary definition. If any downstream entitlement or compliance requirement depends on the term "dispensary", ensure that the physical area in question is demonstrably "dedicated to storing and dispensing medicines" (sch.1-sec.1). Where space is shared, document the extent of dedicated use, signage, access controls or standard operating procedures that evidence the area's dedication to those functions.

7. Anticipate higher-tier consequences and restructure only with legal advice. If the objective is to secure tier 1 or tier 2 classification, be mindful that changes to applicant composition, corporate involvement, or trusteeship may move an application into tier 3. Because the schedule gives no fee or process detail, do not assume restructuring is costless; seek advice before reorganising ownership or corporate participation.

8. Keep contemporaneous records for audit or review. Given the schedule’s silence on enforcement but the practical likelihood of verification, retain corporate registers, trust deeds, power of attorney documents and minutes that corroborate the stated status for at least the period in which the application will be processed.

9. Monitor for fee provisions and procedural directions elsewhere. The schedule includes a Fees heading without content (sch.2-pt.2). Practitioners must locate the complementary fee provisions or administrative rules that will operationalise the tiers, and ensure payment or fee-exemption compliance as required elsewhere.

10. Where doubts remain, obtain a written classification or preliminary ruling from the administering authority. The schedule creates deterministic criteria but leaves process and proof unspecified. A written statement from the decision-maker that confirms tier status will reduce risk, but the schedule does not itself create a right to such a statement; the availability of such a procedure will depend on other instruments.

These steps translate the schedule’s limited textual mandates into concrete actions an applicant should take to prepare an application that can be classified reliably under sch.2-sec.1 and to show that any area claimed as a dispensary meets the schedule’s definition (sch.1-sec.1).